ライフサイエンスコーパス: rifaximin

1 dtB-Rif + NAC) but not rifaximin alone (CdtB-Rifaximin).

2 with that of vancomycin, metronidazole, and rifaximin.

3 d pharmacologic treatment with lactulose and rifaximin.

4 es in patients with MHE after treatment with rifaximin.

5 size these MMIPs for selective extraction of rifaximin.

6 were minimally affected in 19 patients post-rifaximin.

7 apacity (43.20 mg g(-1)) and selectivity for rifaximin.

8 is, compared with simvastatin 20 mg/day plus rifaximin.

9 ,011 dynes x s/cm(5) ) revealed no effect of rifaximin.

10 to study the efficacy and safety profile of rifaximin.

11 at treatment with the nonsystemic antibiotic rifaximin.

12 S symptoms with antibiotic therapy including rifaximin.

13 bo, over a 6-month period (hazard ratio with rifaximin, 0.42; 95% confidence interval [CI], 0.28 to 0

14 < 0.01) and receiving antibiotics other than rifaximin (10.5 days; p < 0.01) were associated with lon

15 00 mg/day (n=18), simvastatin 20 mg/day plus rifaximin 1200 mg/day (n=16), or placebo of both medicat

16 domly assigned to simvastatin 40 mg/day plus rifaximin 1200 mg/day (n=18), simvastatin 20 mg/day plus

17 tients (16 in the simvastatin 40 mg/day plus rifaximin 1200 mg/day group, 14 in the simvastatin 20 mg

18 imin 1200 mg/day, simvastatin 20 mg/day plus rifaximin 1200 mg/day, or placebo of both medications fo

19 to receive either simvastatin 40 mg/day plus rifaximin 1200 mg/day, simvastatin 20 mg/day plus rifaxi

20 signed to receive simvastatin, 20 mg/d, plus rifaximin, 1200 mg/d (n = 117), or identical-appearing p

21 ons), levofloxacin (500 mg; 111 persons), or rifaximin (1650 mg; 107 persons), in combination with lo

22 emission then began maintenance therapy with rifaximin 200 mg/day (to 1800 mg/day) for up to 24 month

23 uadalajara, Mexico, 210 U.S. adults received rifaximin (200 mg/d, 200 mg twice daily, or 200 mg 3 tim

24 were randomly assigned to receive 400 mg of rifaximin 3 times daily for 10 days (n = 43) or placebo

25 patients (44.1%) who responded to open-label rifaximin, 382 (35.6%) did not relapse and 692 (64.4%) d

26 romycin, 3.8 hours; levofloxacin, 6.4 hours; rifaximin, 5.6 hours).

27 responding to a 2-week course of open-label rifaximin 550 mg 3 times daily, who then relapsed during

28 ssigned to groups given repeat treatments of rifaximin 550 mg or placebo 3 times daily for 2 weeks.

29 le outpatients with cirrhosis and ascites to rifaximin 550 mg twice a day (n = 36) or placebo twice a

30 Of patients given rifaximin, 91% improved their cognitive performance, com

31 Rifaximin, a gut-targeted antibiotic, improves cognitive

32 We evaluated rifaximin, a minimally absorbed antibiotic, as treatment

33 The efficacy of rifaximin, a minimally absorbed antibiotic, is well docu

34 discuss the potential mechanism of action of rifaximin, a minimally absorbed antibiotic.

35 Rifaximin, a non-absorbable antibiotic used in managing

36 Rifaximin, a nonabsorbable antibiotic that decreases lip

37 The efficacy of rifaximin, a nonabsorbed antimicrobial agent, was demons

38 rated by an improved synthetic strategy, and rifaximin, a potent PXR agonist, demonstrated that conic

39 ces screening (OR 1.20 [1.13, 1.27]), use of rifaximin after a discharge for hepatic encephalopathy (

40 ng, endoscopic varices screening, and use of rifaximin after hospitalization for hepatic encephalopat

41 However, Rifaximin allowed a higher intestinal microbiome diversi

42 ith rifaximin + NAC (CdtB-Rif + NAC) but not rifaximin alone (CdtB-Rifaximin).

43 ized clinical trials assessing the effect of rifaximin, alone or in combination with other drugs, on

44 conditional recommendations for eluxadoline, rifaximin, alosetron, (moderate certainty), loperamide (

45 review of the following agents: eluxadoline, rifaximin, alosetron, loperamide, tricyclic antidepressa

46 Rifaximin altered microbiota diversity and composition,

47 Oral rifaximin altered the composition of bacterial communiti

48 estraint stressors, and investigated whether rifaximin altered the gut microbiota, prevented intestin

49 Rifaximin alters the bacterial population in the ileum o

50 Rifaximin, an antibiotic of the ansamycin class has been

51 Rifaximin, an oral, non-systemic, broad-spectrum antibio

52 a developed in 14.74% of participants taking rifaximin and 53.70% of those taking placebo (rate ratio

53 has been an increased interest in the use of rifaximin and albumin in various settings of ArLD.

54 ARGs are not affected by rifaximin and are associated with hospitalizations and d

55 cted mucosal breaks in 20% of subjects given rifaximin and in 43% of subjects given placebo (P = .05

56 For patients with HE, 32.4% and 63.3% filled rifaximin and lactulose, respectively.

57 d ALT between the simvastatin 20 mg/day plus rifaximin and placebo group (for AST -14 IU/L [-91 to 64

58 tes of adverse events were comparable in the rifaximin and placebo groups.

59 e azithromycin, effectiveness of single-dose rifaximin, and emerging resistance to front-line agents

60 Both FDX and OP-1118 (unlike vancomycin, rifaximin, and metronidazole) effectively inhibited spor

61 rmacological treatments such as antibiotics (rifaximin), anti-inflammatory drugs (mesalazine) and pro

62 Rifaximin appears promising as a chemoprophylaxis for tr

63 Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapie

64 there were no significant changes within the rifaximin arm.

65 e there was no significant change within the rifaximin arm.

66 and 1.9% in azithromycin, levofloxacin, and rifaximin arms, respectively) (P = .55).

67 74.8% of the levofloxacin, azithromycin, and rifaximin arms, respectively.

68 findings challenge the conventional view of rifaximin as a low-risk intervention and support mechani

69 Patients' response to rifaximin as a maintenance therapy appears to be favorab

70 onstipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times da

71 Among patients not on rifaximin at enrollment, GPB reduced the proportion of p

72 In contrast, vancomycin, metronidazole, and rifaximin (at similar sub-MICs) did not inhibit sporulat

73 from chronic liver disease to receive either rifaximin, at a dose of 550 mg twice daily (140 patients

74 study is needed in Asia to determine whether rifaximin can prevent diarrhea caused by invasive bacter

75 th CdtB and treated with placebo (CdtB-PBS), rifaximin (CdtB-Rifaximin), or rifaximin + NAC (CdtB-Rif

76 g simulator performance after treatment with rifaximin, compared with placebo.

77 erimental and clinical evidence suggest that rifaximin could have other beneficial effects on the cou

78 mics in patients with cirrhosis and ascites; rifaximin did not affect glomerular filtration rate or l

79 Four weeks of treatment with rifaximin did not reduce the hepatic venous pressure gra

80 , respectively (P < 0.001 for both), and all rifaximin doses were superior to placebo.

81 mucolytic N-acetylcysteine (NAC) to improve rifaximin efficacy.

82 us omeprazole (20 mg once daily), and either rifaximin-EIR (400 mg) or placebo, twice daily for 14 da

83 f patients who received the 800-mg dosage of rifaximin-EIR (61 of 98) were in remission, compared wit

84 ients given the 400-mg and 800-mg dosages of rifaximin-EIR had low rates of withdrawal from the study

85 Administration of 800 mg rifaximin-EIR twice daily for 12 weeks induced remission

86 Data from patients given rifaximin-EIR were compared with those from individuals

87 efficacy and safety of 400, 800, and 1200 mg rifaximin-EIR, given twice daily to 402 patients with mo

88 ents given the 400-mg and 1200-mg dosages of rifaximin-EIR, respectively; these rates did not differ

89 ion and support mechanistic evidence linking rifaximin exposure to cross-resistance against critical

90 ine whether a gastroresistant formulation of rifaximin (extended intestinal release [EIR]) induced re

91 er a delayed-release antibiotic formulation (rifaximin-extended intestinal release [EIR]) prevents th

92 nvenient and reliable method for trace-level rifaximin extraction from milk using eco-friendly MMIPs.

93 Rifaximin followed by systemic antibiotics maintained mi

94 eatment predominantly involves lactulose and rifaximin following rigorous treatment of so-called know

95 had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS

96 dence in the literature regarding the use of rifaximin for different gastrointestinal disorders.

97 However, the use of rifaximin for prevention or treatment of other complicat

98 ine kinase in the simvastatin 20 mg/day plus rifaximin group (4.2 IU/L [-804 to 813]; p=0.992).

99 tly higher in the simvastatin 40 mg/day plus rifaximin group (nine [56%] of 16 patients) compared wit

100 None of the subjects in the rifaximin group developed large lesions, compared with 9

101 rematurely in the simvastatin 40 mg/day plus rifaximin group due to recommendations by the data safet

102 A total of 13.6% of the patients in the rifaximin group had a hospitalization involving hepatic

103 addition, significantly more patients in the rifaximin group had a response to treatment as assessed

104 ge-liver disease scores, but patients in the rifaximin group had increased levels of the anti-inflamm

105 Patients in the simvastatin 40 mg/day plus rifaximin group showed a significant increase in AST and

106 Patients in the simvastatin 40 mg/day plus rifaximin group showed an increase in creatine kinase at

107 Significantly more patients in the rifaximin group than in the placebo group had adequate r

108 Similarly, more patients in the rifaximin group than in the placebo group had adequate r

109 lopathy occurred in 22.1% of patients in the rifaximin group, as compared with 45.9% of patients in t

110 drivers were randomly assigned to placebo or rifaximin groups and followed up for 8 weeks (n = 42).

111 rifaximin or the simvastatin 20 mg/day plus rifaximin groups compared with placebo.

112 Rifaximin had no effect on hepatic venous pressure gradi

113 Rifaximin has been shown to be of benefit to these patie

114 ative options to standard therapies, whereas rifaximin has demonstrated success in uncontrolled trial

115 Simvastatin and rifaximin have shown beneficial effects in liver cirrhos

116 f fusidic acid and bacitracin and, possibly, rifaximin if resistance to this agent becomes widespread

117 Rifaximin improves IBS symptoms for up to 10 weeks after

118 n was more effective than only lactulose and rifaximin in improving grades of HE, recovery time from

119 nvestigated the efficacy and tolerability of rifaximin in maintaining symptomatic and endoscopic remi

120 We also studied ARGs pre- and 8 weeks post-rifaximin in patients with compensated cirrhosis in an o

121 Treatment with simvastatin 40 mg/day plus rifaximin in patients with decompensated cirrhosis was a

122 multiple pathogenic events, the efficacy of rifaximin in the prevention or management of complicatio

123 nt doses of simvastatin, in combination with rifaximin, in patients with decompensated cirrhosis.

124 This study explores how rifaximin influences gut microbiota functions and its as

125 Rifaximin is a gastrointestinal-selective antibiotic wit

126 Rifaximin is a poorly absorbed antimicrobial with activi

127 Rifaximin is an oral nonsystemic antibiotic with minimal

128 Rifaximin is currently approved in the United States for

129 Rifaximin is currently used worldwide in patients with c

130 Rifaximin is effective for the treatment of travelers' d

131 Future studies should evaluate whether rifaximin is effective in preventing postinfectious irri

132 Rifaximin is FDA-approved for treatment of irritable bow

133 Rifaximin is gaining attention for its potential activit

134 Rifaximin is increasingly important as a therapy for hos

135 One difference from rifaximin is the site of delivery of AEMCOLO which appea

136 Rifaximin is used to treat patients with functional gast

137 jor morbidity despite standard of care (SOC; rifaximin/lactulose).

138 Over the 8-week study period, patients given rifaximin made significantly greater improvements than t

139 Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopat

140 Intestinal decontamination with rifaximin may improve hemodynamics.

141 -one patients began maintenance therapy with rifaximin (median dose 200 mg/day); 33 (65%) maintained

142 group, 14 in the simvastatin 20 mg/day plus rifaximin mg/day group, and 14 in the placebo group).

143 In immune nonresponders to ART, rifaximin minimally affected microbial translocation and

144 ulation and decrease portal hypertension and rifaximin modulates the gut microbiome and might prevent

145 We propose that rifaximin modulates the ileal bacterial community, reduc

146 3-IS levels compared to mono-antibiosis with Rifaximin (n = 14) or intravenous Vancomycin (n = 4, not

147 ly assigned to receive repeat treatment with rifaximin (n = 328) or placebo (n = 308).

148 Compared with no study treatment (n = 22), rifaximin (n = 43) use was associated with a significant

149 zed to a combination of LOLA, lactulose, and rifaximin (n = 70) or placebo, lactulose, and rifaximin

150 ifaximin (n = 70) or placebo, lactulose, and rifaximin (n = 70).

151 variability normalized in rats treated with rifaximin + NAC (CdtB-Rif + NAC) but not rifaximin alone

152 o (CdtB-PBS), rifaximin (CdtB-Rifaximin), or rifaximin + NAC (CdtB-Rif + NAC) for 10 days.

153 le and treated with placebo (Control-PBS) or rifaximin + NAC (Control-Rif + NAC, safety), or inoculat

154 The optimal rifaximin + NAC combination was then tested in a validat

155 and disease progression, study the effect of rifaximin on ARG burden, and compare ARGs in cirrhosis w

156 controlled trial investigates the effects of rifaximin on hemodynamics, renal function, and vasoactiv

157 the first part with the potential impact of rifaximin on pathogenic mechanisms in liver diseases, wh

158 e between the the simvastatin 40 mg/day plus rifaximin or the simvastatin 20 mg/day plus rifaximin gr

159 ted with placebo (CdtB-PBS), rifaximin (CdtB-Rifaximin), or rifaximin + NAC (CdtB-Rif + NAC) for 10 d

160 ering therapy by l-ornithine l-aspartate and rifaximin orally for 4 weeks.

161 Noninferiority could not be shown with rifaximin (P = .07).

162 mortality (P < .001) for patients receiving Rifaximin plus systemic antibiotics compared to other ty

163 Rifaximin prevents travelers' diarrhea with minimal chan

164 Rifaximin provided 72% and 77% protection against travel

165 ut normalized in CdtB-Rif + NAC but not CdtB-Rifaximin rats.

166 score, gender, use of antibiotics other than rifaximin, reason for admission and hepatitis C are pred

167 In addition, rifaximin recipients had a lower bloating score after tr

168 Over the 10 weeks of follow-up, rifaximin resulted in greater improvement in IBS symptom

169 Mono-antibiosis with Rifaximin revealed higher 3-IS levels (P < .001), higher

170 Rifaximin safely prevented travelers' diarrhea in Mexico

171 Rifaximin significantly influenced gut microbiota and pr

172 ups that did not report travelers' diarrhea, rifaximin significantly reduced the occurrence of mild d

173 Rifaximin significantly reduced the risk of an episode o

174 of responders was significantly greater with rifaximin than placebo (38.1% vs 31.5%; P = .03).

175 2%; P = .018) was significantly greater with rifaximin than placebo, but not stool consistency (51.8%

176 Eighty participants completed rifaximin therapy or placebo, and follow-up data were av

177 Rifaximin therapy was not cost-saving at current prices

178 changes in coliform flora were found during rifaximin therapy.

179 hronic pouchitis, studies found success with rifaximin, tinidazole, and oral budesonide.

180 The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes

181 Rifaximin treatment also significantly reduced the risk

182 atients receiving other antibiotics prior to rifaximin treatment exhibit greater AMR risks.

183 cacy and safety data from clinical trials of rifaximin treatment of IBS.

184 e five colonized patients received long-term rifaximin treatment to prevent hepatic encephalopathy.

185 the 5 colonized patients received long-term rifaximin treatment to prevent hepatic encephalopathy.

186 nts with relapsing symptoms of IBS-D, repeat rifaximin treatment was efficacious and well tolerated.

187 Rifaximin trial: ARG abundance patterns were minimally a

188 onstrate a two-fold AMR risk associated with rifaximin use (HR = 1.89; 95% CI = 1.49-2.40), with sign

189 t study, we evaluate the association between rifaximin use and subsequent AMR in patients with cirrho

190 Rifaximin use is also associated with an escalated risk

191 ing evidence raised concerns that widespread rifaximin use may promote antimicrobial resistance (AMR)

192 score, serum sodium, albumin, lactulose use, rifaximin use, and benzodiazepine/barbiturate sedation.

193 significant bacterial resistance will limit rifaximin use.

194 unts <350 cells/mm(3) were randomized 2:1 to rifaximin versus no study treatment for 4 weeks.

195 )T-cell activation (median change, 0.0% with rifaximin vs +0.6% with no treatment; P = .03).

196 stration of carbon tetrachloride (CCl4), and rifaximin was administered daily.

197 Rifaximin was found to be safe and well tolerated in lon

198 Rifaximin was found to lead to better maintenance of rem

199 Rifaximin was found to lead to better maintenance of rem

200 Combination of LOLA with lactulose and rifaximin was more effective than only lactulose and rif

201 Although rifaximin was slightly more effective than lactulose in

202 Twenty subjects on lactulose/rifaximin were randomized 1:1.

203 ent of irritable bowel syndrome-diarrhoea is rifaximin, which was approved in May 2015.

204 Treatments considered were lactulose or rifaximin, which were assumed to reduce the MVA rate to

205 with cirrhosis, including 59 already taking rifaximin, who had experienced two or more hepatic encep

206 Single-dose azithromycin, levofloxacin, and rifaximin with loperamide were comparable for treatment

207 In a resazurin checkerboard assay, combining rifaximin with NAC had significant synergistic effects i

208 These findings suggest that combining rifaximin with NAC may improve the percentage of IBS-D p

209 ups (Rifaximin without systemic antibiotics, Rifaximin with systemic antibiotics, and Ciprofloxacin/M

210 antibiotic activity, we formed 3 subgroups (Rifaximin without systemic antibiotics, Rifaximin with s